DelMar Pharmaceuticals Announces the Completion of Enrollment in its Phase II Expansion Study of VAL-083 in Refractory Glioblastoma Multiforme Oct 21, 2015
DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer Oct 19, 2015
DelMar Pharmaceuticals to Present Data on the Promising Potential of VAL-083 in the Treatment of Pediatric Brain Tumors Sep 29, 2015
DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015 Sep 28, 2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme at GBM2015 Sep 10, 2015
DelMar Pharmaceuticals Presents Clinical Protocol for Advancement of VAL-083 into Phase IV Studies as a Treatment for Non-Small Cell Lung Cancer Sep 8, 2015
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update Sep 4, 2015
DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer Sep 2, 2015
